A multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of CS-917 [Daiichi Sankyo Inc] as monotherapy for type 2 diabetes
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs CS 917 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 02 Aug 2007 Status changed from in progress to completed.
- 05 Feb 2007 Status change
- 01 Oct 2006 New trial record.